logo

For the Inventor, By the Inventor

Indianapolis, IN, United States of America

Sandra K Sigmund

USPTO Granted Patents = 11

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 28(Granted Patents)


Location History:

  • Carmel, IN (US) (1989 - 1991)
  • Indianpolis, IN (US) (1998)
  • Indianapolis, IN (US) (1988 - 2001)

Company Filing History:

goldMedal11 out of 4,449 
 
Eli Lilly and Company
 patents

Years Active: 1988-2001

Loading Chart...
11 patents (USPTO):Explore Patents
1. 6251928 - Treatment of alzheimer's disease employing inhibitors of cathepsin D (2001-06-26),
2. 5747517 - Benzylidene rhodanines (1998-05-05),
3. 5550118 - Polyhydronorharman synthase inhibitors (1996-08-27),
4. 5468757 - 6-azaindole thromboxane synthase inhibitors (1995-11-21),
5. 5011938 - 7-substituted bicyclic pyrazolidinones (1991-04-30),
6. 4940718 - 7-substituted bicyclic pyrazolidinones, pharmaceutical compositions and (1990-07-10),
7. 4902707 - Bicyclic pyrazolidinones, compositions and use (1990-02-20),
8. 4826992 - 2,3-(Dihydro) bicyclic pyrazolidinones (1989-05-02),
9. 4820723 - Disubstituted tetrazole leukotriene antagonists and methods for their (1989-04-11),
10. 4777299 - Process for leukotriene antagonists (1988-10-11),
11. 4777298 - Process for intermediates to leukotriene antagonists (1988-10-11),

Title: **The Innovative Mind of Sandra K. Sigmund**

Introduction

Sandra K. Sigmund, an accomplished inventor located in Indianapolis, IN, has made significant contributions to the field of medical research. With a remarkable portfolio of 11 patents, she is recognized for her innovative solutions aimed at treating challenging diseases, specifically Alzheimer's disease.

Latest Patents

One of Sandra's latest patents focuses on the Treatment of Alzheimer’s Disease employing inhibitors of cathepsin D. This groundbreaking invention introduces novel benzylidene rhodanines that serve as agents in treating or preventing conditions associated with beta-amyloid peptide. The methods outlined in this patent involve administering an effective amount of these compounds to a mammal in need, highlighting the potential impact of her work on therapeutic strategies for Alzheimer’s.

Another significant patent from Sandra showcases additional applications of benzylidene rhodanines. This invention reiterates their role as useful agents in tackling conditions linked to beta-amyloid peptide and further emphasizes the methods for treating or preventing Alzheimer’s Disease.

Career Highlights

Sandra K. Sigmund works at Eli Lilly and Company, a leading organization in pharmaceutical advancements. Her work is at the intersection of innovation and practical treatment solutions, contributing to Eli Lilly's reputation for tackling some of the most pressing health issues facing society today.

Collaborations

Throughout her career, Sandra has collaborated with notable professionals such as Celia A. Whitesitt and Louis Nickolaus Jungheim. These collaborations not only enhance the depth of her research but also foster a creative environment conducive to innovation in the field of pharmaceutical sciences.

Conclusion

Sandra K. Sigmund continues to push the boundaries of medical research and innovation with her patents and ongoing collaborative efforts. Her dedication to improving treatment options for Alzheimer's disease exemplifies the crucial role inventors play in advancing healthcare solutions for the benefit of society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…